Company: ADZCF
Filing Date: 2025-01-17
Form Type: 424B2
Source: 0000950103-25-000655
Chunk: 20

Company: DEUTSCHE BANK AKTIENGESELLSCHAFT
Filing Date: 2025-01-17
Form: 424B2
Chunk 20
---
 may also       
 be more susceptible to adverse developments related to their products or services.                                                            |

Risks Relating to Conflicts of Interest

| · | Trading and Other Transactions by Us, UBS or Our or Its Affiliates in the                                                                        
 Equity and Equity Derivative Markets May Impair the Value of the Securities — We or our                                                          
 affiliates expect to hedge our exposure from the Securities by entering into equity and equity derivative transactions, such as over-the-counter 
 options, futures or exchange-traded instruments with one or more hedge counterparties, which will include UBS or its affiliates. We,             
 UBS or our or its affiliates may also engage in trading in instruments linked or related to the Underlying on a regular basis as part            
 of our or their general broker-dealer and other businesses, for proprietary accounts, for other accounts under management or to facilitate       
 transactions for customers, including block transactions. Such trading and hedging activities may adversely affect the level of the Underlying   
 and, therefore, make it less likely that you will receive a positive return on your investment in the Securities. It is possible that            
 we, UBS or our or its affiliates could receive substantial returns from these hedging and trading activities while the value of the Securities   
 declines. We, UBS or our or its affiliates may also issue or underwrite other securities                                                         
 or financial or derivative instruments with returns linked or related to the Underlying. To the extent that we, UBS or our or its affiliates     
 serve as issuer, agent or underwriter for such securities or financial or derivative instruments, our, UBS’ or our or its                        
 affiliates’ interests with respect to such products may be adverse to those of the holders of the Securities. Introducing competing              
 products into the marketplace in this manner could adversely affect the level of the Underlying and the value of the Securities.                 
 Any of the foregoing activities described in this paragraph may reflect trading strategies that differ from, or are in direct opposition         
 to, investors’ trading and investment strategies related to the Securities. Furthermore, because DBSI, UBS or one of its affiliates              
 is expected to conduct trading and hedging activities for us in connection with the Securities, DBSI, UBS or such affiliates may profit          
 in connection with such trading and hedging activities and such profit, if any, will be in addition to any compensation that DBSI or UBS         
 receives for the sale of the Securities to you. You should be aware that the potential to earn a profit in connection with hed